GUIYANG XINTIAN PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.12 CNY | -2.67% |
|
-6.94% | -26.81% |
| Jun. 03 | Xintian Pharmaceutical Gets Nod to Trial Chronic Non-Bacterial Prostatitis Drug; Shares Down 3% | MT |
| May. 14 | Guiyang Xintian Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -26.81% | 275M | - | ||
| +19.43% | 80.67B | A | ||
| +13.63% | 9.17B | A- | ||
| -15.14% | 4.86B | A- | ||
| +45.17% | 4.55B | - | ||
| +15.70% | 4.34B | B- | ||
| +11.63% | 2.38B | B | ||
| -26.13% | 2.2B | C- | ||
| +15.73% | 2.1B | - | - | |
| -40.52% | 1.86B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 002873 Stock
- Ratings Guiyang Xintian Pharmaceutical Co.,Ltd.
